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Abstract 
Context. Cancer pain can appear with spikes of higher intensity. Breakthrough cancer 
pain (BTCP) is the most common term for the transient exacerbations of pain, but the ability 
of the nomenclature to capture relevant pain variations and give treatment guidance is 
questionable. 
Objectives. To reach consensus on definitions, terminology, and sub classification of 
transient cancer pain exacerbations. 
Methods. The most frequent authors on BTCP literature were identified using the 
same search strategy as in a systematic review and invited to participate in a two-round 
Delphi survey. Topics with a low degree of consensus on BTCP classification were refined 
into twenty statements. The participants rated their degree of agreement with the statements 
on a numeric rating scale (NRS 0-10). Consensus was defined as a median NRS score of ≥ 7 
and an interquartile range of ≤ 3.  
Results. Fifty-two authors had published three or more papers on BTCP over the past 
ten years. Twenty-seven responded in the first round and 24 in the second round. Consensus 
was reached for 13 of 20 statements. Transient cancer pain exacerbations can occur without 
background pain, when background pain is uncontrolled, and regardless of opioid treatment. 
There exist cancer pain exacerbations other than BTCP, and the phenomenon could be named 
“episodic pain”. Patient reported treatment satisfaction is important with respect to 
assessment. Sub classification according to pain pathophysiology can provide treatment 
guidance.  
Conclusion. Significant transient cancer pain exacerbations include more than just 
BTCP. Patient input and pain classification are important factors for tailoring treatment.  
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Introduction 
Cancer pain can be caused by the cancer itself or by cancer therapy. Tissue damage 
may occur in sites such as bone, viscera, and nerve structures and sometimes call for specific 
treatment strategies. Intermittent spikes of higher pain intensity may occur, most often named  
breakthrough cancer pain (BTCP) (1).  The definitions used for BTCP  assume a stable or 
controlled background pain (1). However, also when the background pain is not controlled, 
cancer pain may fluctuate. 
The prevalence of BTCP varies between studies (2). Factors other than differences in 
symptom and disease burden might influence the reported prevalence. These factors include 
differences in definitions and diagnostic criteria (3, 4), and inclusion of patients with poorly 
controlled background pain (5).  
The concept of BTCP involves the presence of a controlled background pain and 
short periods of higher pain intensity, or transient cancer pain exacerbations. Algorithms for 
diagnosing BTCP have been proposed (6-8). Still there are unsolved issues both regarding 
definitions and terminology of transient cancer pain exacerbations. There is no agreement on 
how to classify transient cancer pain exacerbations appearing without background pain. 
Furthermore, there is no universal agreement on the upper limit of pain intensity of a 
controlled background pain or the magnitude of increase in pain intensity for a transient 
cancer pain exacerbation to be clinically significant. And although the issue has been 
addressed (9, 10), there is no agreement on classification of transient pain exacerbations 
according to pain pathophysiology or etiology. Discrepancies on definitions and diagnostic 
criteria may influence the use and interpretation of classification systems.  
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Based on the unresolved issues identified in a systematic review (1), and with the overall 
aim of a higher degree of consensus on definitions and terminology, a Delphi survey was 
undertaken among international experts on BTCP. The study addresses the following 
research questions: 
1. How should transient cancer pain exacerbations be defined? 
2. How should transient cancer pain exacerbations be termed? 
3. How could transient cancer pain exacerbations be sub classified in order to guide 
treatment?   
Methods 
A two-round international Delphi expert survey was performed from February to May 
2015.  The participants, identified by a literature search performed in PubMed using the same 
strategy as in a recent systematic review on BTCP (1), were the most frequent authors on the 
subject over the past ten years. Delphi surveys may have low response rates (11, 12), and a 
predefined initial number of approximately 50 experts was chosen to ensure a final sample 
size large enough for valid results (13) (Fig. 1). The authors and co-authors on BTCP articles 
were contacted by email and invited to participate in a web survey. Two reminders were 
mailed to non-responders in both rounds, and the survey was closed one week after the final 
reminder. 
The selection of  issues to be addressed  was initially based upon areas with low 
degree of consensus identified in a systematic literature review on assessment and 
classification of BTCP (1). These areas included the question of opioid medication as a 
prerequisite for the diagnosis of BTCP, the issue of controlled background pain and how to 
measure it, and the lack of a formal classification system. The authors of this paper further 
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discussed these issues and formulated twenty statements (Table 1) for the Delphi survey. 
This work was done on behalf of the European Association for Palliative Care Research 
Network (EAPC RN). 
The study participants were asked to rate their agreement with the statements on an 
eleven point numeric rating scale (NRS 0-10), with the anchors, “do not agree at all” and 
“completely agree”, respectively. Based on previous research and in accordance with the 
study protocol (14, 15), the statements reaching a median score of less than seven (NRS 0-
10) or an inter-quartile range (IQR) of more than three were reassessed, except for statements 
were the participants universally did not agree with the statement (median NRS 0). The 
median NRS rating and the IQR for each statement in the previous round were disclosed to 
the participants in the second round. According to a priori agreement and in line with 
recently published research (12, 15), consensus was defined as a median NRS (0-10) score of 
seven or more and an IQR of three or less. The results are reported as medians and IQRs of 
the agreement with the statements (16).   
Results 
Fifty-two authors and co-authors had published three or more papers on BTCP over 
the past ten years and were eligible for the study (Fig. 1). The contact details were 
unavailable for four authors, therefore an invitation mail was sent to 48 potential participants. 
Two authors declined participation due to lack of clinical experience, leaving 46 potential 
respondents. After two reminders, 27 respondents provided complete answers to the first 
round.  After two reminders, 24 respondents provided complete answers to the second round.  
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Consensus was reached for 11 statements in the first round (Table 1). In addition, 
there was a unison disagreement with two statements.  After reassessment in the second 
round, consensus was reached for two more, resulting in consensus on 13 of 20 statements.   
Regarding the statements on definitions, consensus was reached in the first round for: 
“Transient cancer pain exacerbation is possible without significant background pain” (NRS 
9.0, IQR 3.0), ”Significant transient cancer pain exacerbation is possible without 
background pain being controlled” (NRS 10.0, IQR 3.0), and “Significant transient cancer 
pain exacerbation can occur in patients currently not on opioids” (NRS 10.0, IQR 2.0). 
Consensus was also reached in the first round for the statements: “Background pain is best 
described as controlled when the patient is satisfied with the overall pain control the around 
the clock pain medication provides” (NRS 8.0, IQR 3.0), and “A significant transient cancer 
pain exacerbation can best be assessed by the patient’s wish/need for rescue medication” 
(NRS 7.0, IQR 3.0). 
For statements on terminology, consensus was reached in the first round for the 
statements: “An overarching concept for all significant transient cancer pain exacerbations 
will contribute to standardization in assessment and classification” (NRS 7.0, IQR 3.0), and 
“The term episodic pain could serve as an overarching concept for all significant transient 
cancer pain exacerbations” (NRS 7.0, IQR 3.0).  
Finally, consensus was reached in the first round for all the statements on 
subclassification: “ A sub grouping of transient cancer pain exacerbations will provide better 
opportunities for a more precise diagnosis and better tailored treatment” (NRS 8.0, IQR 
3.0), “Identification of transient cancer pain exacerbations due to bone metastases can affect 
treatment choices” (NRS 9.0, IQR 2.0), “Identification of transient cancer pain 
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exacerbations due to neuropathic pain can affect treatment choices” (NRS 9.0, IQR 2.0), 
and “Identification of transient cancer pain exacerbations due to visceral pain can affect 
treatment choices” (NRS 9.0, IQR 3.0).  
There was a unanimous disagreement with two of the statements: “An increase in 
pain intensity of one point on an NRS scale (0-10) is a significant transient cancer pain 
exacerbation” (NRS 0.0, IQR 2.0), and “Background pain is best described as controlled 
when the pain intensity is 6 or less on an NRS scale (0-10)” (NRS 0.0, IQR 2.0). Those 
statements were not reassessed. 
Two statements on definitions and terminology reached consensus after reassessment 
in the second round (1. and 2. round, respectively): “The increase in pain intensity on an NRS 
scale (0-10) has to be more than two points for the transient cancer pain exacerbation to be 
significant” (NRS 7.0, IQR 5.0 and NRS 7.0, IQR 3.0), and “There are significant cancer 
pain exacerbations other than breakthrough pain (NRS 9.0, IQR 5.0 and NRS 8.0, IQR 
2.75). 
For five statements consensus could not be reached (1. and 2. round, respectively): 
“An increase in pain intensity of two points on an NRS scale (0-10) is a significant transient 
cancer pain exacerbation” (NRS 4.0, IQR 4.0 and NRS 5.0, IQR 3.75), “A significant 
transient cancer pain exacerbation can best be assessed by a percentage increase in NRS 
score” (NRS 5.0, IQR 6.0 and NRS 5.0, IQR 5.0), “A significant transient cancer pain 
exacerbation can best be assessed by an increase in NRS score to a certain predefined 
number” (NRS 5.0, IQR 6.0 and NRS 5.0, IQR 3.0),  “Background pain is best described as 
controlled when the background pain intensity is 4 or less on an NRS scale (0-10)” (NRS 
7.0, IQR 6.0 and NRS 6.0, IQR 3.0), and “ Background pain is best described as controlled 
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when the background pain intensity is 3 or less on an NRS scale (0-10)”, (NRS 7.0, IQR 5.0 
and NRS 7.5, IQR 6.75). 
Discussion 
Controversy and disagreement regarding basic definitions of transient cancer pain 
exacerbations persist (1). This Delphi survey provided consensus on several key statements. 
That is, short-lived episodes of more severe cancer pain can occur both without background 
pain as well as when the background pain is not controlled, regardless of opioid treatment. 
Furthermore, patient reported treatment satisfaction is important when defining controlled 
background pain and significant transient cancer pain exacerbations. However, consensus 
was not reached for most statements specifying numerical pain intensity scores. The 
existence of transient cancer pain exacerbations other than BTCP was recognized. The 
benefit of an overarching term comprising all such transient pain exacerbations was 
acknowledged, and the suggestion that the term “episodic pain” could serve the purpose was 
endorsed. Finally, consensus was reached for the importance of identifying 
pathophysiological mechanisms of transient cancer pain exacerbations.                                                                           
In some former definitions, regularly administered opioid medication was suggested 
as a prerequisite for BTCP (17). In more recent literature, this requirement has generally been 
abandoned (6, 7, 10, 18). The current definitions of BTCP require the presence of a 
background pain, and that the background pain has an intensity below a defined level, e.g. 
NRS (0-10) ≤ 4 (7). A multicenter prevalence study explored the effect of different levels of 
background pain on the prevalence of transient cancer pain exacerbations (episodic pain) (5). 
When comparing patients with any background pain intensity to a sub group of the 
population with an average background pain of NRS (0-10) ≤ 6, a higher prevalence of 
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episodic pain was found when including patients regardless of background pain intensity 
level. This result supports our consensus finding that transient cancer pain exacerbation, or 
episodic pain, is possible irrespective of background pain intensity.  
Patient-reported outcome measures (PROMs) are essential assessments in oncology 
and palliative medicine, and should capture clinically important data and be responsive to 
change over time (19). Extensive work has been undertaken to identify meaningful cut-off 
points for pain intensity measurements, including pain exacerbation and pain relief, and 
different cut points and methods to measure changes in pain intensity have been suggested 
(20-25). The lack of consensus on the statements presenting specific cut-off points for BTCP 
intensity and meaningful changes in pain intensities must be interpreted in the light of the 
ongoing research. Also the definition of a controlled background pain is currently being 
discussed  (26), and the absence of consensus must be viewed against this background. 
Several papers have applied the criterion not more than “mild” intensity for a controlled 
background pain (6, 8, 18). In even more recent research controlled background pain is 
defined as NRS(0-10) ≤ 4 (7), based on previous findings (24).   
The international Delphi panel reached agreement on the statements implying that the 
best description of pain as controlled or in need for further treatment is the patient’s 
satisfaction with the ongoing medication or wish for further medication, respectively. 
BTCP has been recognized as a spectrum of very different entities (6). Within the 
international expert panel there was consensus that there are intermittent pain flares other 
than BTCP, and support for the idea of “episodic pain” as an overarching term for all such 
transient pain exacerbations. Episodic pain was previously suggested as a clinical entity by 
EAPC (27). In a topical review preceding the latest update of the International Classification 
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of Diseases (ICD-11), cancer pain is described as continuous (background pain) or 
intermittent (episodic pain) (28), in line with the consensus reached in this study. 
Different pain etiologies and pathophysiological mechanisms may call for different 
treatment modalities, as affirmed in this study. Although underused, single fraction 
radiotherapy is efficacious in palliating uncomplicated bone metastases (29). Neuropathic 
pain, associated with an unpredictable response to conventional analgesic treatment, can 
potentially be relieved by addition of specific adjuvant drugs (15). Furthermore, episodic 
pain with visceral etiology is an important finding in patients with abdominal cancer (30). 
Also in the topical review preceding the latest ICD-11 update (28), the importance of pain 
etiology, pathophysiology, and body site is emphasized. Moreover, the principle of multiple 
parenting is introduced, allowing the same diagnosis to be subsumed under more than one 
category. In clinical practice, the diagnostic process can be guided by important symptom 
descriptors and PROMs followed by a symptom diagnosis with related pathophysiology and 
etiology (Fig. 2). 
Only approximately 50% of the eligible authors responded in both rounds. Although 
expected (11, 12), this is a clear limitation of the study. And even though authors of papers 
on BTCP will have special insights in this field of research, a risk of including participants 
with limited clinical experience was present. Additionally, no input was obtained from the 
patients.   
In conclusion; transient pain exacerbations can occur independently of background 
pain level, ongoing pain medication, and include more than BTCP only. The phenomenon 
could be named “episodic pain” and sub classified according to pathophysiology. Patient 
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reported treatment satisfaction is important both when assessing background and episodic 
pain. 
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Table: Statements and Consensus Ratings 
Consensus reached in favor of the statement 1.round  2.round 
NRSa IQRb 
 
NRSa IQRb 
Definitions 
 
   
Significant transient cancer pain exacerbation can occur in patients 
currently not on opioids 
 
10.0 2.0    
Significant cancer pain exacerbation is possible without the 
background pain being controlled 
 
10.0 3.0    
Transient cancer pain exacerbation is possible without significant 
background pain 
 
9.0 3.0    
Background pain is best described as controlled when the patient is 
satisfied with the overall pain control the around the clock medication 
provides 
 
8.0 3.0    
A significant transient cancer pain exacerbation can best be 
assessed by the patient’s wish/need for rescue medication 
 
7.0 3.0    
The increase in pain intensity on an NRS scale (0-10) has to be more 
than two points for the transient cancer pain exacerbation to be 
significant 
 
 
7.0 5.0    7.0 3.0 
Terminology 
   
 
An overarching concept for all significant transient cancer pain 
exacerbations will contribute to standardization in assessment and 
classification 
 
    
7.0 
   
3.0 
   
The term episodic pain could serve as an overarching concept for all 
significant transient cancer pain exacerbations 
 
7.0 3.0    
There are significant cancer pain exacerbations other than 
breakthrough pain 
 
 
9.0 5.0    8.0 2.75 
Sub classification 
   
 
Identification of transient cancer pain exacerbations due to bone 
metastases can affect treatment choices 
 
    
9.0 
   
2.0 
   
Identification of transient cancer pain exacerbations due to 
neuropathic pain can affect treatment choices 
 
9.0 2.0    
Identification of transient cancer pain exacerbations due to visceral 
pain can affect treatment choices 
 
9.0 3.0    
A sub grouping of transient cancer pain exacerbations will provide 
better opportunities for a more precise diagnosis and better tailored 
8.0 3.0    
                                                          
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
treatment 
 
 
No consensus in favor of the statement 
 
Background pain is best described as controlled when the 
background pain intensity is 3 or less on an NRS scale (0-10) 
 
7.0 5.0    7.5 6.75 
Background pain is best described as controlled when the 
background pain intensity is 4 or less on an NRS scale (0-10) 
 
7.0 6.0    6.0 3.0 
A significant transient cancer pain exacerbation can best be 
assessed by a an increase in NRS score to a certain predefined 
number 
 
5.0 6.0    5.0 3.0 
A significant transient cancer pain exacerbation can best be 
assessed by a percentage increase in NRS score 
 
5.0 6.0    5.0 5.0 
An increase in pain intensity of two point on an NRS scale (0-10) is a 
significant transient cancer pain exacerbation 
 
4.0 4.0    5.0 3.75 
An increase in pain intensity of one point on an NRS scale (0-10) is a 
significant transient cancer pain exacerbation c  
 
0.0 2.0    
Background pain is best described as controlled when the 
background pain intensity is 6 or less on an NRS scale (0-10) d 
0.0 2.0    
 
                                                          
a
  NRS: Numeric Rating Scale (0-10), median 
b
  IQR: Inter-Quartile Range 
cd
 Statement not reassessed in the second round 
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Figure 1: Participant inclusion 
             
 
       First round                                                                                     Second round 
 
a
 
                                                          
a
 BTCP: Breakthrough Cancer Pain 
52 authors published 
≥ 3 papers on BTCP 
over the past ten 
years 
4 missing addresses 
27 authors 
answered the 
survey 
 
48 authors identified 
by email addresses 
2 declined participation 
46 potential 
respondents 
19 did not respond 
27 respondents 
from 1. round invited 
3 did not respond 
24 authors 
answered the 
survey  
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Figure 2: Cancer pain (multiple parenting); Diagnostic workup 
 
 
a
                                                          
a
 PROMs: Patient Reported Outcome Measures 
 
•Somatic nociceptive 
pain
•Visceral nociceptive 
pain
•Neuropathic pain
•Caused by the cancer 
•Caused by the cancer 
treatment
•Non-cancer related 
•PROMs
•Anamnesis
•Physical examination
•Labs
• Imaging
• Continuous/Episodic
• Intensity
• Localisation
• Quality
• Duration, frequency etc.
• Treatment satisfaction
Pain Diagnostic workup
Patho-
physiologyEtiology
